YS BIOPHARMA CO LTD (YS) Stock Income Statement
USA - NASDAQ:YS - KYG9845F1090 - Common Stock
1.02 USD
+0.11 (+12.45%)
1.07 USD
+0.05 (+4.9%)
| 2023 (2023-3-31) | 2022 (2021-12-31) | 2021 (2020-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|
| Revenue | 687.20M | 0.00 | 0.00 | 0.00 | |||
| Cost Of Goods | 153.36M | 117.07M | N/A | N/A | |||
| Gross Profit | 533.84M | 385.88M | N/A | N/A | |||
| Operating Expenses | 673.22M | 556.83K | 3.64K | 3.64K | |||
| Research and Development | 318.70M | 211.22M | N/A | N/A | |||
| Selling, General, and Administrative Expenses | 354.52M | 549.18K | 549.18K | N/A | |||
| Operating Income | -139.38M | -556.83K | -3.64K | -3.64K | |||
| Interest Income/Expense | -30.86M | -3.28M | -3.28M | N/A | |||
| Other Income/Expense | 25.89M | 3.29M | 3.29M | N/A | |||
| Non Recurring Items | N/A | 0.00 | 0.00 | N/A | |||
| Income Before Taxes | -144.35M | -545.73K | -3.64K | -3.64K | |||
| Income Tax | 1.13M | 4.94M | N/A | N/A | |||
| Net Income | -283.47M | -545.73K | -3.64K | -3.64K | |||
| EBITDA | -102.69M | 30.60M | N/A | N/A | |||
| Per Share Data | |||||||
| EPS Diluted Total Ops | -3.05 | -0.03 | -0.00 | -0.00 | |||
| Statistics | |||||||
| Gross Profit Margin | 77.68% | N/A | N/A | N/A | |||
| Profit Margin | -41.25% | N/A | N/A | N/A | |||
| Operating Profit Margin | -20.28% | N/A | N/A | N/A | |||
All data in CNY